Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Radiotherapy and temozolomide for anaplastic astrocytic gliomas.

Nayak L, Panageas KS, Reiner AS, Huse JT, Pentsova E, Braunthal SG, Abrey LE, DeAngelis LM, Lassman AB.

J Neurooncol. 2015 May;123(1):129-34. doi: 10.1007/s11060-015-1771-8. Epub 2015 Apr 29.

2.

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.

Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M; NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society.

Lancet Oncol. 2012 Jul;13(7):707-15. doi: 10.1016/S1470-2045(12)70164-X. Epub 2012 May 10.

3.

MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.

Sadones J, Michotte A, Veld P, Chaskis C, Sciot R, Menten J, Joossens EJ, Strauven T, D'Hondt LA, Sartenaer D, Califice SF, Bierau K, Svensson C, De Grève J, Neyns B.

Eur J Cancer. 2009 Jan;45(1):146-53. doi: 10.1016/j.ejca.2008.09.002. Epub 2008 Oct 20.

PMID:
18945611
4.

Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.

Speirs CK, Simpson JR, Robinson CG, DeWees TA, Tran DD, Linette G, Chicoine MR, Dacey RG, Rich KM, Dowling JL, Leuthardt EC, Zipfel GJ, Kim AH, Huang J.

Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):268-76. doi: 10.1016/j.ijrobp.2014.10.027.

PMID:
25636755
5.

Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813.

Chang S, Zhang P, Cairncross JG, Gilbert MR, Bahary JP, Dolinskas CA, Chakravarti A, Aldape KD, Bell EH, Schiff D, Jaeckle K, Brown PD, Barger GR, Werner-Wasik M, Shih H, Brachman D, Penas-Prado M, Robins HI, Belanger K, Schultz C, Hunter G, Mehta M.

Neuro Oncol. 2017 Feb 1;19(2):252-258. doi: 10.1093/neuonc/now236.

6.

Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.

Jastaniyah N, Murtha A, Pervez N, Le D, Roa W, Patel S, Mackenzie M, Fulton D, Field C, Ghosh S, Fallone G, Abdulkarim B.

Radiat Oncol. 2013 Feb 20;8:38. doi: 10.1186/1748-717X-8-38.

7.

Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation.

Capdevila L, Cros S, Ramirez JL, Sanz C, Carrato C, Romeo M, Etxaniz O, Hostalot C, Massuet A, Cuadra JL, Villà S, Balañà C.

J Neurooncol. 2014 Mar;117(1):77-84. doi: 10.1007/s11060-013-1352-7. Epub 2014 Jan 7.

PMID:
24395350
8.

Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era.

Paravati AJ, Heron DE, Landsittel D, Flickinger JC, Mintz A, Chen YF, Huq MS.

J Neurooncol. 2011 Aug;104(1):339-49. doi: 10.1007/s11060-010-0499-8. Epub 2010 Dec 22.

9.

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.

Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M.

J Clin Oncol. 2009 Dec 10;27(35):5874-80. doi: 10.1200/JCO.2009.23.6497. Epub 2009 Nov 9. Erratum in: J Clin Oncol. 2010 Feb 1;28(4):708.

PMID:
19901110
10.

Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.

Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.

Neurosurg Focus. 2014 Dec;37(6):E4. doi: 10.3171/2014.9.FOCUS14502.

PMID:
25434389
11.

Long term experience in high grade glial tumors with temozolomide.

Demirci U, Buyukberber S, Coskun U, Akmansu M, Yaman E, Baykara M, Yamac D, Uner A, Benekli M.

J BUON. 2012 Apr-Jun;17(2):357-62.

PMID:
22740218
12.

Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131.

Vogelbaum MA, Berkey B, Peereboom D, Macdonald D, Giannini C, Suh JH, Jenkins R, Herman J, Brown P, Blumenthal DT, Biggs C, Schultz C, Mehta M.

Neuro Oncol. 2009 Apr;11(2):167-75. doi: 10.1215/15228517-2008-073. Epub 2008 Sep 8.

13.

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.

Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krueger S, Picard M, Weller M.

J Clin Oncol. 2010 Jun 1;28(16):2712-8. doi: 10.1200/JCO.2009.26.6650. Epub 2010 May 3.

PMID:
20439646
14.

Prolonged administration of temozolomide in adult patients with anaplastic glioma.

Freyschlag CF, Smolczyk DR, Janzen E, Schmieder K, Thomé C, Lohr F, Wenz F, Weiss C, Tuettenberg J, Seiz M.

Anticancer Res. 2011 Nov;31(11):3873-7.

PMID:
22110212
15.

Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide.

Shonka NA, Theeler B, Cahill D, Yung A, Smith L, Lei X, Gilbert MR.

J Neurooncol. 2013 Jun;113(2):305-11. doi: 10.1007/s11060-013-1116-4. Epub 2013 Mar 23.

PMID:
23526410
16.

The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma.

Kizilbash SH, Giannini C, Voss JS, Decker PA, Jenkins RB, Hardie J, Laack NN, Parney IF, Uhm JH, Buckner JC.

J Neurooncol. 2014 Oct;120(1):85-93. doi: 10.1007/s11060-014-1520-4. Epub 2014 Jul 4.

17.
18.

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R; Nordic Clinical Brain Tumour Study Group (NCBTSG).

Lancet Oncol. 2012 Sep;13(9):916-26. Epub 2012 Aug 8.

PMID:
22877848
19.

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.

Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA.

J Clin Oncol. 1999 Sep;17(9):2762-71. Erratum in: J Clin Oncol 1999 Nov;17(11):3693.

PMID:
10561351
20.

A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas.

Kumthekar P, Grimm S, Chandler J, Mehta M, Marymont M, Levy R, Muro K, Helenowski I, McCarthy K, Fountas L, Raizer J.

J Neurooncol. 2017 Jul;133(3):589-594. doi: 10.1007/s11060-017-2469-x. Epub 2017 May 16.

PMID:
28510787

Supplemental Content

Support Center